CHMP recommends EU approval of Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Once approved,Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the phase I/II NP30179 study, whereColumvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is part of Roche ’s industry-leading CD20xCD3 T-cell-engaging bispecific developmentprogramme, which aims to transform the treatment experience for people with blood cancers using off-the-shelf and fixed-duration optionsBasel, 26 ...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news
CHMP recommends EU approval of Roche ’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma
Once approved,Columvi will be the first CD20xCD3 T-cell-engaging bispecific antibody available to treat people in Europe with this aggressive lymphomaThe recommendation is based on results from the phase I/II NP30179 study, whereColumvi given as a fixed course induced early and long-lasting complete responses in people with heavily pre-treated or refractory diffuse large B-cell lymphoma1Columvi is part of Roche ’s industry-leading CD20xCD3 T-cell-engaging bispecific developmentprogramme, which aims to transform the treatment experience for people with blood cancers using off-the-shelf and fixed-duration optionsBasel, 26 ...
Source: Roche Media News - April 26, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of Polivy (first-line treatment for an aggressive form of blood cancer)EU approva...
Source: Roche Investor Update - April 26, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19 tests
Basel, 26 April 2023As expected, significantly lower demand for COVID-19 tests leads to a decrease inGroup sales (-3%1 at constant exchange rates [CER] and -7% in Swiss francs); excluding this effect, Group sales grow 8%Pharmaceuticals Divisionsales up 9%; strong demand for newer medicines; Vabysmo for severe eye diseases is already the strongest growth driverDiagnostics Division base business grows 4%, whiledivisional salesare 28% lower due to exceptionally high demand for COVID-19 tests in the first quarter of 2022Highlights in the first quarter:US approval of Polivy (first-line treatment for an aggressive form of blo...
Source: Roche Media News - April 26, 2023 Category: Pharmaceuticals Source Type: news
Cancer Risk Increased With Exposure to Four or More CT Scans by Age 18
MONDAY, April 24, 2023 -- Exposure to four or more computed tomography (CT) scans before age 18 years is associated with increased risk of subsequent intracranial tumors, leukemia, and lymphoma, according to a study published online April 24 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 24, 2023 Category: Pharmaceuticals Source Type: news
How Many CT Scans Are Safe for Kids?
MONDAY, April 24, 2023 -- Getting a single CT scan during childhood doesn ’t appear to increase a child ' s risk of a future brain tumor, leukemia or lymphoma, new research finds, but getting four or more scans more than doubles the chances.
CT scans... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 24, 2023 Category: General Medicine Source Type: news
Antibody-Drug Conjugate Gets FDA Thumbs Up for Untreated DLBCL
(MedPage Today) -- The FDA approved the antibody-drug conjugate (ADC) polatuzumab vedotin (Polivy) plus standard therapy for certain types of untreated diffuse large B-cell lymphoma (DLBCL), according to a statement from Genentech.
The approval... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 20, 2023 Category: American Health Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche ’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma
Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin lymphoma in the USPOLARIX trial showed thePolivy combination reduced the risk of disease progression, relapse or death by 27% compared to the standard of care, R-CHOP, with a comparable safety profileFirst-line treatment withPolivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progressionBasel, 19 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that t...
Source: Roche Investor Update - April 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche ’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma
Polivy combination is the first FDA-approved therapy in nearly 20 years for the first-line treatment of diffuse large B-cell lymphoma, an aggressive disease and the most common form of non-Hodgkin lymphoma in the USPOLARIX trial showed thePolivy combination reduced the risk of disease progression, relapse or death by 27% compared to the standard of care, R-CHOP, with a comparable safety profileFirst-line treatment withPolivy plus R-CHP has the potential to reduce the burden on patients and healthcare systems, associated with disease progressionBasel, 19 April 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that t...
Source: Roche Media News - April 19, 2023 Category: Pharmaceuticals Source Type: news
PET/MRI cuts breast cancer scan times in half
PET/MRI breast cancer imaging time can be cut in half without losing key diagnosti...Read more on AuntMinnie.comRelated Reading:
PET/MRI shows heart inflammation after COVID-19 vaccination
PET/MRI an effective alternative to PET/CT for lymphoma management
Brain PET/MRI scans reveal visual snow syndrome
Pylarify PET/MRI shows value in selecting patients for focal ablative therapy
PET/MRI shows promise for imaging infection, inflammation (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 17, 2023 Category: Radiology Source Type: news
Pulmonary Lymphoma Presenting As a Cavitary Mass in COVID-19 Pulmonary Lymphoma Presenting As a Cavitary Mass in COVID-19
This case highlights the challenges of safely and expeditiously diagnosing and treating aggressive cancers of the respiratory tract in patients acutely infected with SARS-CoV-2.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 7, 2023 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news
PET/CT reveals vascular effects of chemotherapy in lymphoma patients
PET/CT imaging has shown for the first time in a clinical trial that aorti...Read more on AuntMinnie.comRelated Reading:
PET tracer uptake related to COVID-19 vaccines detected in lymphoma patients
PET/MRI an effective alternative to PET/CT for lymphoma management
PET radiomics predict relapse in lymphoma patients
FDG-PET/MRI offers option for pediatric Hodgkin lymphoma
PET is useful modality in patients with lymphomas (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 7, 2023 Category: Radiology Source Type: news
Update on IMBRUVICA ® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics, an AbbVie Company, announced today the intent to voluntarily withdraw the U.S. indications for IMBRUVICA® (ibrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This decision was made in consultation with the U.S. Food and Drug Administration (FDA), c...
Source: Johnson and Johnson - April 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Episode 4: CAR T Cells and Immunotherapy in Mantle Cell Lymphoma Episode 4: CAR T Cells and Immunotherapy in Mantle Cell Lymphoma
Drs Peter Martin and Michael Wang discuss the role of CAR T cells in mantle cell lymphoma, how they are used with respect to bridging therapy, and the surveillance and management of toxicities.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 30, 2023 Category: Consumer Health News Tags: Hematology-Oncology InDiscussion Source Type: news
Pre-Existing Heart Failure Tied to Higher Mortality in Lymphoma
(MedPage Today) -- Patients with diffuse large B-cell lymphoma (DLBCL) and pre-existing heart failure (HF) were less likely to receive standard -- but cardiotoxic -- anthracycline treatment, likely resulting in worse survival outcomes, according... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 29, 2023 Category: Cardiology Source Type: news
